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Open access under CC BYFukutin-I is a member of a family of putative O-linked glycosyltransferases linked to the glycosylation of
the dystrophin complex. Mutations in this family of proteins have been linked to a number of congenital
muscular dystrophies that arise from the hypoglycosylation of a-dystroglycan. Critical to the function of
Fukutin and other members of this family is their localisation within the cell, which has been shown to
depend critically on the interactions between the N-terminal transmembrane domain of these proteins
and the lipid bilayer within the ER/Golgi. To investigate how the interactions between the N-terminal
transmembrane domain and the lipid bilayer regulate the localisation of Fukutin-I, we have developed
an efﬁcient expression and puriﬁcation protocol in Escherichia coli to allow biophysical studies to be per-
formed. Expressing the N-terminal domain of Fukutin-1 fused to a His6 tag resulted in the localisation of
the protein to the bacterial membrane. A puriﬁcation strategy has been developed to isolate the highly
hydrophobic transmembrane domain of Fukutin-1 from the membrane with yields of approximately
4 mg per litre of minimal media. Preliminary biophysical analyses have conﬁrmed the identity of the pep-
tide and revealed that in hydrophobic solvents mimicking the bilayer, the peptide adopts a well-struc-
tured a-helix as predicted from the sequence.
 2010 Elsevier Inc. Open access under CC BY license. Introduction
Recently, a number of genes have been identiﬁed that are in-
volved in the O-linked glycosylation of a-dystroglycan (aDG)1, an
important component of the dystrophin associated complex that an-
chors muscle ﬁbres to the extracellular scaffold [1], these genes in-
clude fukutin, fukutin related protein, LARGE, POMGnT1, POMT1 and
POMT2. Mutations in these genes have been shown to result in the
aberrant glycosylation of aDG resulting in a broad spectrum of con-
genital muscular dystrophies [1]. Sequence analysis suggests that
these genes encode for Type-II membrane proteins with putative
glycosyltransferase activity, an observation consistent with the
hypoglycosylation of aDG detected in patients carrying mutations
in any of these genes [1]. Subsequent studies have revealed that
these proteins are normally located within the ER/Golgi complex
in agreement with their proposed role in the glycosylation of aDG
[2–5]. Interestingly, a number of the mutations associated with these
genes result in the miss-localisation within the cell [3] suggesting. Williamson).
ermosensitive alkaline phos-
D-thiogalactopyranoside; PBS,
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eteronuclear single-quantum
 license. that their retention within the ER/Golgi complex is vital for the
appropriate glycosylation of aDG.
The retention of proteins, including glycosyltransferases, within
the ER and Golgi is a highly dynamic process reliant on the tight
regulation of both antero- and retrograde transport steps [6]. Se-
quence analysis and biochemical analyses have demonstrated that
retrograde transport is largely regulated by the receptor mediated
recognition of speciﬁc peptide motifs on the extra-membranous
domains of ER and Golgi resident proteins [6]. In contrast, regula-
tion of anterograde transport appears to be dependent on the
shorter N-terminal transmembrane domain (TMD) that is typically
found in ER and Golgi resident proteins [6]. It has been proposed
that this interaction between the shortened N-terminal TMD and
the atypical lipid composition found within the ER and Golgi com-
plex plays an important role in regulating anterograde trafﬁcking
[7,8]. Indeed, in the context of muscular dystrophy, the N-terminal
transmembrane domains of the proteins encoded by fukutin and
fukutin related protein have been shown to be sufﬁcient to retain
the protein within the Golgi complex [9].
Although the role of theN-terminal TMD in the retention of these
proteins isnowknown,amolecularunderstandingof thisprocess re-
mains to be elucidated. Several models based on lipid-mediated
sorting and protein oligomerisation have been proposed
[6,8,10,11]. To understand at a molecular level how lipids regulate
protein trafﬁcking, we are studying the transmembrane domain of
the putative glycosyltransferase linked to Fukuyamamuscular dys-
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proteins, the transmembrane domain of Fukutin has been demon-
strated to be sufﬁcient for the targeting of the protein to the Golgi
apparatus [9]. Using a combination of liquid, solid-state NMRmeth-
ods and other biophysical techniques, we are investigating how the
differences in lipid bilayer composition affect the structure, oligo-
meric state and lateral segregation of Fukutin’s transmembrane
domain.
A pre-requisite to these studies is the introduction of NMR sen-
sitive isotopes into the protein of interest. Until recently, solid-
state NMR studies of transmembrane peptides and proteins have
relied on the introduction of labels site-selectively using solid-
phase peptide synthesis. This technique permits the preparation
of peptides up to 50 residues in length in milligram quantities suf-
ﬁcient for biophysical characterisation. However, recent advances
in both liquid and solid-state NMR methodology rely on the uni-
form incorporation of NMR sensitive isotopes within the protein
or peptides, a process that is costly when using solid-phase peptide
synthesis, as uniformly labelled amino acids are required.
To exploit these advances in NMR methodology in the study of
how lipids regulate Fukutin-1 trafﬁcking, we have sought to devel-
op an efﬁcient bacterial expression system which permits both
uniform and selective and extensive labelling of the transmem-
brane domain of Fukutin-1 thereby avoiding the synthesis of uni-
formly labelled peptide [12,13]. The expression and puriﬁcation
of transmembrane peptides and proteins is notoriously difﬁcult
due to their hydrophobicity and potential toxicity to the host cell
[14]. To overcome these difﬁculties a number of groups have uti-
lized carrier proteins to aid solubility, reduce toxicity and in some
cases target the protein/peptide to the bacterial membranes [14].
However, it is our experience that after puriﬁcation the yields ob-
tained can be low as the desired peptides represent only a small
fraction of the overall fusion protein and signiﬁcant losses can be
incurred during puriﬁcation. Here we report on an efﬁcient expres-
sion and puriﬁcation method for the transmembrane domain of
Fukutin-1 using simply a His6 tag for puriﬁcation. Even in the ab-
sence of a classical bacterial membrane protein targeting sequence,
the peptide is effectively targeted to the bacterial membrane pre-
sumably due to the intrinsic sequence and is expressed in quanti-
ties sufﬁcient to support biophysical characterisation and
introduction of isotopes for subsequent NMR studies.Materials and methods
Restriction enzymes Sph1, Pst1 and Dpn1, Pfu polymerase, T4
DNA ligase, thermosensitive alkaline phosphatase (TSAP) were
purchased from Promega, UK. The pQE32 vector and M15 [PREP]
Escherichia coli strain were bought from Qiagen, UK. The detergent,
dodecylmaltoside (DDM) was supplied by Anatrace. Puriﬁcation
reagents were obtained from Sigma. 15NH4Cl and 13C-glucose were
bought from Goss Scientiﬁc, UK. Oligonucleotides and sequencing
analyses were obtained from Euroﬁns, MWG, UK.Construction of the expression plasmid
The protein sequence (MQRINKNVVL ALLTLTSSAF LLFQLYYYKH
YLSARN) corresponding to the transmembrane domain of Fukutin-1
(UniProtKB ID: Q8R507) with associated ﬂanking regions was re-
verse-translatedwithoptimalcodonusage forE. coli togeneratea syn-
thetic gene corresponding to the transmembrane domain of Fukutin-
1. The oligonucleotide sequence was chemically synthesized and
cloned into thepGS-21avector (Genescript,NewJersey,USA). Forpro-
tein expression, the gene was cloned into the pQE32 vector. The se-
quence encoding the FK1TMD was ampliﬁed by standard PCR at an
annealing temperature of 61 C using the forward primer GAT-ATCGCATGCATGAGCCGTA and the reverse primer GTGGTGCTGCAGT
TAGTTACGC [15]. The primers were designed to introduce the Sph1
and Pst1 restriction sites at the 50 and 30 end of the coding sequence,
respectively. Followingdigestionof thePCRproductwithSphIandPstI,
the puriﬁedPCRproductwas ligated into thepre-digestedpQE32vec-
tor at a molar ratio 3:1 resulting in the His6-FK1TMD plasmid, subse-
quently referred to as FK1TMD. The ligation mix was used to
transform competent M15 [PREP4] E. coli cells. The sequence of the
FK1TMD plasmid was subsequently veriﬁed by DNA sequencing.
Overexpression of FK1TMD
An overnight culture (10 mL) of M15 E. coli transformed with
the FK1TMD containing plasmid was grown on LB containing
100 lg/mL ampicillin and kanamycin 50 lg/mL at 37 C. The over-
night culture was used to inoculate 1 L LB medium supplemented
with antibiotics and grown at 37 C to an OD600 of 0.6. FK1TMD
peptide overexpression was subsequently induced for 4 h at
37 C by the addition of isopropyl-b-D-thiogalactopyranoside
(IPTG) to a ﬁnal concentration of 1 mM. For 15N and 13C-labelled
FK1TMD, the overnight cultures were spun down and resuspended
in 250 mL of M9 minimal medium containing 1 g/L 15NH4Cl and
3 g/L 13C-glucose, respectively instead of LB medium [15] and
grown to OD600 of 0.6. The culture was then diluted to 1 L labelled
minimal medium and grown to an OD600 of 0.6. Expression was in-
duced by the addition of IPTG to a ﬁnal concentration of 1 mM and
grown for a further 4 h. Cells were harvested at 4 C by centrifuga-
tion at 12000g for 20 min and pellet was stored at 20 C.
Puriﬁcation of FK1TMD
The cell pellet was resuspended and lysed in 40 mL phosphate
buffered saline (PBS) containing 50 mM imidazole and 1 mM phe-
nylmethylsulphonyl ﬂuoride (PMSF), pH 7.5 and sonicated on ice
for 5 min: 15 s on; 20 s off at power level 7 (Misonix sonicator).
The lysate was clariﬁed by ultracentrifugation at 142,000g for
35 min. The pellet was resuspended in 50 mL solubilisation buffer
(PBS containing 20 mM DDM, 50 mM imidazole, pH 7.5) for 1 h at
roomtemperature. The solubilised fractionwas clariﬁedby centrifu-
gation at 21,000g and the supernatant loaded onto a Ni2+-NTA afﬁn-
ity column (GE Healthcare) pre-equilibrated with lysis buffer. The
column was washed with 15 bed volumes of washing buffer (PBS,
200 mM imidazole, 1 mM DDM, pH 7.5) and the peptide eluted in
PBS containing 600 mM imidazole and 1 mM DDM, pH 7.5. The
eluted fractions were analysed by SDS–PAGE using a 20% tricine
gel at 125 V for 90 min [16]. Gels were stained with Sypro-Orange
(Invitrogen) in 10% acetic acid for 40 min. After destaining in 10%
acetic acid for2 min, thegelwasvisualisedusingaUV transillumina-
tor. For Western Blot analysis the destained proteins were trans-
ferred to a polyvinylidene ﬂuoride (PVDF) membrane using a
voltage of 70 V for 25 min. The fusion protein was detected using
an antibody against polyhistidine (Sigma) at a dilution of 1:4000.
Toprecipitate the protein out of solution, itwas dialyzed against dis-
tilled deionized water using a 2 kDamolecular weight cut-off Slide-
a-lyzer dialysis cassette (GE Healthcare). Three buffer exchanges
(2 h each) were performed to remove imidazole and to dilute DDM
to a concentration below its CMC (170 lM). The pellet was collected
after centrifugation at 229,000g for 30 min and washed with dis-
tilled water. The peptide was then dissolved in acetonitrile:water
(50:50) containing 0.1% triﬂuoroacetic acid (TFA) and lyophilized
to white powder.
Circular dichroism
The CD spectrum of FK1TMD peptide dissolved in triﬂuoroeth-
anol (Sigma) to a ﬁnal concentration of 0.15 mg/mL was measured
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quartz cuvette (Hellma) at room temperature. The spectrum scan
was performed from 300 to 190 nm using a spectral bandwidth
of 2 nm, scanning speed of 100 nmmin1 and 4 s response time.
Data was analysed using the CONTILL analysis algorithm on the
DichroWeb server [17] using the reference dataset 4.
Mass spectrometry
The purity of the peptide FK1TMD was conﬁrmed by mass spec-
trometry. Mass spectra were recorded on an LCTTM (Waters, UK)
orthogonal acceleration time-of-ﬂight mass spectrometer ﬁtted
with a nano electospray source. FK1TMD in TFE (5 pmol/ll, 5 ll)
was loaded into borosilicate capillaries (1.2 mm o.d.  0.69 mm
i.d.) (Clark Electromedical Instruments, Reading, UK) that had been
drawn to a ﬁne tip using a micro-electrode puller (Narishige, To-
kyo, Japan) and sputter coated with gold/palladium. Spectra were
recorded in the positive ion mode between 600–1500m/z using
the following instrument settings: capillary 1200 V, sample cone
35 V, extraction cone 9 V, source temperature 50 C. Typically,
100 spectra were combined and deconvoluted using the maximum
entropy algorithm MaxEntTM (Micromass, Altrincham, UK) to give
relative molecular mass spectra over the range 5000–7000 Da at
1 Da resolution. Spectra were externally calibrated using NaI/CsI
spectra recorded under identical conditions immediately after each
sample.
Liquid-state NMR
Liquid-state NMR spectra were acquired on a Varian Inova
600 MHz spectrometer equipped with a triple resonance probe
equipped with gradients at 35 C. The sample was prepared by dis-
solving 4 mg of the lyophilized FK1TMD in 0.5 mL d2-triﬂuoroeth-
anol. 1H/15N HSQC spectra were acquired with states phase
sensitive detection in the indirect dimension. Spectra were ac-
quired with 40 (t1, 15N) by 639 (t2, 1H) complex data points in eachFig. 1. Schematic representation of the expression casdimension with spectral widths of 2 and 10 kHz, respectively. The
data was processed using NMRPipe [18]. Indirect dimension data
points were linear predicted to 128 data points and a sine-bell
squared ﬁlter applied in both the direct and indirect dimensions.
The resulting data was zero-ﬁlled before Fourier transformation
to give a data matrix of 512 by 4096.Results and discussion
Construct design and expression
The expression cassette for the expression of FK1TMD and an
overview of the cloning strategy are given in Fig. 1. DNA sequenc-
ing results conﬁrmed the insertion of the FK1TMD gene into the
pQE32 vector and the absence of point mutations. After transfor-
mation of M15 [PREP4] competent cells with the FK1TMD expres-
sion plasmid, the optimal expression conditions for FK1TMD in LB
medium were determined by monitoring bacterial growth and
expression time courses under varying temperature and IPTG con-
centrations and analyzing the resulting cell lysates byWestern Blot
using an antibody against the His6 tag (data not shown). Optimal
peptide expression was observed following induction for 4 h with
1 mM IPTG as shown by Western blot using an antibody that rec-
ognises the His6 tag (Fig. 2A). The FK1TMD ran as a single mono-
meric band of approximately 6.0 kDa. An additional high
molecular weight endogenous bacterial protein is also recognised
by the antibody against the His6 tag. For experiments which re-
quired uniformly labelled with 13C-carbon and 15N-nitrogen, over-
night culture was grown in LB medium, spun down and grown up
to 1 L in minimal medium in two stages as described above.Puriﬁcation of FK1TMD
Preliminary analysis with cell lysate revealed that FK1TMD was

















Fig. 2. Analysis of the expression and puriﬁcation of FK1TMD. (A) Western blot
analysis showing the induction of FK1TMD following the addition of IPTG. 1 ml
aliquot of pre- (i) and post- (ii) induction cell lysate was probed with anti-His6
antibody (1:4000). (B) Tricine gel (20%) of a typical puriﬁcation of FK1TMD using
Ni-NTA afﬁnity column stained with the ﬂuorescent SYPRO-Orange. Lane 1,
molecular weight markers; Lanes 2 and 3, uninduced (5 lL) and induced bacterial
cell lysate (15 lL); Lane 4, solubilised membrane fraction (5 lL); Lane 5, ﬁnal wash
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the membrane fraction with the non-ionic detergent, DDM, for
1 h. The FK1TMD was subsequent puriﬁed by Ni-NTA afﬁnity chro-
matography. The yield of the pure peptide eluted from the Ni2+-
NTA afﬁnity column was 4 ± 2 mg/L as determined by a standard
BCA assay (Bio-rad) (Table 1). We note that extraction with alter-
native detergents, in particular Triton 100, resulted in higher
yields of puriﬁed protein. However, these detergents proved difﬁ-
cult to remove hindering subsequent analysis by electrospray mass
spectroscopy. The puriﬁed FK1TMD was subsequently precipitated
out of solution by dialysis against deionised water until the DDM
concentration was below its CMC of 170 lM. After pelleting of
the insoluble material and washing with deionized water, the
resulting peptide was dissolved in 50:50 acetonitrile:water with
0.05% TFA and lyophilised to a white ﬂuffy powder. In this form,
the pellet was ready for further characterisation.Table 1
Puriﬁcation of FK1TMD. Figures given are for a 1 L growth on LB and are
representative of three separate trials.
Fraction Protein content (mg) Purity (%)
Mass of wet cell pellet 5200
Cell lysate 560
Solubilized membrane fraction 148
FK1TMD after Ni-afﬁnity
chromatography
4.0 95The purity of the peptide was veriﬁed on a 20% SDS–PAGE tri-
cine gel using Sypro-Orange ﬂuorescent stain with the dominant
band from FK1TMD running slightly higher than expected at
approximately 6.0 kDa (Fig. 2B). The endogenous E. coli protein
identiﬁed by Western blot analysis also bound to the Ni2+-NTA
afﬁnity column and was removed by a high stringency wash with
200 mM imidazole prior to elution of the FK1TMD resulting in a ﬁ-
nal purity in excess of 95% as determined from the gel. It is noted
that Sypro-Orange staining offered improved detection over Com-
massie for hydrophobic peptides presumably reﬂecting the more
hydrophilic nature of the solvents used which prevents the disso-
lution of the hydrophobic peptide from the gel. The enhanced
detection with Sypro-Orange proved invaluable for the efﬁcient
detection of the FK1TMD.
FK1TMD labelled with 15N and/or 13C- was prepared from E. coli
harvested from minimal media as described in the material and
methods. Following puriﬁcation the yield was approximately 20%
less that that obtained from similar growths on LB media.
Mass spectroscopic analysis of FK1TMD
The sequence of the FK1TMD peptide including His-tag and lin-
ker region is MRGSHHHHHH GIRMQRINKN VVLALLTLTS SAF-
LLFQLYY YKHYLSARN with a predicted molecular mass of
5,874 Da (Expasy Protparam, [19]). Electrospray mass spectra of
the 15N labelled FK1TMD puriﬁed from DDM always contained a
signiﬁcant contribution from the detergent with peaks correspond-
ing to the H+ and Na+ salts present (Fig. 3A). In addition, peaks aris-Fig. 3. Mass spectrum of the FK1TMD. (A) Spectrum showing the mass to charge
ratios of various species after electrospray mass spectrometry. The labelled peaks
indicate the multiply charged states of FK1TMD. Peaks correlating to the dimers of
the detergent, DDM (MW of 510 Da), associated with the peptide were also
dominant (shown in italics). Data has been normalised to the value obtained for the
largest peak. (B) The deconvoluted spectrum shows a single peak at 5956 Da
corresponding to the molecular weight of the 15N-labelled FK1TMD.
Fig. 4. CD spectrum of FK1TMD in triﬂuoroethanol (0.15 mg ml1) revealing the
expected a-helical conformation for the TMD of FK1 in TFE (solid line, experimen-
tal; dashed, ﬁtted).
Fig. 5. 1H/15N-HSQC resonances of FK1TMD in d2-triﬂuoroethanol at 25 C showing
over 90% of the peaks expected from the 49 residue FK1TMD.
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and 735 corresponding to the 5+, 6+, 7+ and 8+ charged states
respectively (Fig. 3A), with MaxEnt analysis (Fig. 3B) calculating
a peptide mass of 5,956 Da. This is in perfect agreement with the
predicted molecular weight of the peptide given that each of the
82 nitrogens within the peptide is enriched at 99% with nitro-
gen-15.
Circular dichroism
Circular dichroism was used to determine the secondary struc-
ture of FK1TMD peptide in TFE. The CD spectrum possessed two
minima at 208 and 222 nm consistent with the peptide adopting
an a-helical conformation (Fig. 4). Analysis with the Contill algo-
rithm [17] using basis set 4 indicated that the alpha helical content
of FK1TMDwas in the region of 85 ± 15% in TFE with the remainder
composed of disordered, loop and strand structures. This is in good
agreement with the hydropathy analysis (TMPred, Expasy) which
suggests that residues Asn7–Leu32 or 75% of the FK1TMD peptide
should adopt an a-helical conformation in TFE.
Solution-state NMR
1H/15N-heteronuclear single-quantum coherence (HSQC) li-
quid-state NMR spectra [20] were acquired to characterise andconﬁrm the purity of FK1TMD. The spectrum of the lyophilized
FK1TMD peptide dissolved in d2-TFE (4 mg/mL) (Fig. 5) showed
good resolution and peak dispersion. Of the 49 peaks expected that
corresponding to the backbone amide groups 46 were apparent
and resolved. In addition a number of resonances are clearly visible
that arise from nitrogens in the amino acid sidechains. The broad
distribution of resonances within the HSQC spectrum indicates,
as expected, that in TFE the FK1TMD is structured in agreement
with the CD spectra.Conclusion
In this work we have described an efﬁcient method for produc-
tion of the transmembrane domain of the putative glycosyltrans-
ferase Fukutin-1, yielding milligram quantities of peptide on
minimal media making the systems suitable for the production
of the FK1TMD for biophysical analysis including the introduction
of isotopes for NMR experimentation. In contrast to earlier pub-
lished methods that rely on the expression of the transmembrane
domains fused to large carrier proteins, improving solubility and
aiding in both the expression and puriﬁcation, here just a single
His6 tag has been added to the transmembrane domain to aid puri-
ﬁcation with the transmembrane domain of Fukutin-1, apparently
sufﬁcient to target the protein to the bacterial membrane.
Although the overall mass of recombinant protein is less than that
obtained from systems employing larger fusion proteins [14] a
greater percentage mass of the recombinant protein expressed is
the peptide of interest resulting in comparable yields for the ﬁnal
puriﬁed peptide. Furthermore, the smaller afﬁnity tag employed
suggests that, in favourable cases where the His6 tag does not
interfere unduly with the physical properties of the peptide being
studied, the peptide can be used without cleavage from the afﬁnity
tag and subsequent puriﬁcation. We acknowledge that the expres-
sion of the transmembrane domain of integral membrane proteins
will depend greatly on the particular sequence being studied, how-
ever the protocol proposed here offers an alternative route to the
efﬁcient and economic expression and labelling of such domains
for NMR and other biophysical studies. The protocols developed
will allow the investigation into the role interactions between
the N-terminal transmembrane of Fukutin-I and the lipid bilayer
plays in its retention in the ER/Golgi.
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